FDA approval for implantable myopia lens
The EVO Visian Implantable Collamer lens

FDA approval for implantable myopia lens

September 7, 2022 Staff reporters

The FDA has greenlit Staar Surgical’s EVO/EVO+ Visian Implantable Collamer lens for the correction of myopia and myopia with astigmatism.

 

EVO lenses are implanted in the posterior chamber, behind the iris and in front of the patient’s natural crystalline lens. Staar Surgical said the lens is indicated for use in patients 21-45 years of age and preoperative peripheral iridotomy is not necessary. “The EVO lens is additive, provides excellent quality of vision day and night, does not cause dry eye syndrome and is removable by a doctor, if ever so desired,” said Caren Mason, Staar’s CEO. More than one million EVO lenses have already been implanted outside the US and 99.4% of patients surveyed said they would have the procedure again, she added.